Literature DB >> 25150289

Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders.

Sharmilee Gnanapavan, Harald Hegen, Michael Khalil, Bernhard Hemmer, Diego Franciotta, Steve Hughes, Rogier Hintzen, Andreas Jeromin, Eva Havrdova, Hayrettin Tumani, Antonio Bertolotto, Manuel Comabella, Jette Frederiksen, José C Álvarez-Cermeño, Luisa Villar, Daniela Galimberti, Kjell-Morten Myhr, Irena Dujmovic, Franz Fazekas, Carolina Ionete, Til Menge, Jens Kuhle, Geoffrey Keir, Florian Deisenhammer, Charlotte Teunissen, Gavin Giovannoni.   

Abstract

OBJECTIVE: The aim of these guidelines is to make the process of reporting body fluid biomarker studies in neurologic disorders more uniform and transparent, in line with existing standards for reporting research in other biomedical areas. Although biomarkers have been around for decades, there are concerns over the high attrition rate of promising candidate biomarkers at later phases of development.
METHODS: BioMS-eu consortium, a collaborative network working toward improving the quality of biomarker research in neurologic disorders, discussed the merits of standardizing the reporting of body fluid biomarker research. A checklist of items integrating the results of other published guidances, literature, conferences, regulatory opinion, and personal expertise was created to ultimately form a structured summary guidance incorporating the key features.
RESULTS: The summary guidance is comprised of a 10-point uniform reporting format ranging from introduction, materials and methods, through to results and discussion. Each item is discussed in detail in the guidance report.
CONCLUSIONS: To enhance the future development of body fluid biomarkers, it will be important to standardize the reporting of studies. This guideline by the BioMS-eu consortium is aimed at setting a standard for the reporting of future body fluid biomarker research studies in neurologic disorders. We anticipate that following these guidelines will help to accelerate the selection of biomarkers for clinical development.
© 2014 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25150289     DOI: 10.1212/WNL.0000000000000809

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

Review 1.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

Review 2.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

3.  Neuron Specific Enolase, S100-beta protein and progranulin as diagnostic biomarkers of status epilepticus.

Authors:  Aurélie Hanin; Jérôme Alexandre Denis; Valerio Frazzini; Louis Cousyn; Françoise Imbert-Bismut; Benoit Rucheton; Dominique Bonnefont-Rousselot; Clémence Marois; Virginie Lambrecq; Sophie Demeret; Vincent Navarro
Journal:  J Neurol       Date:  2022-02-21       Impact factor: 4.849

Review 4.  Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays.

Authors:  Marta Del Campo; Wesley Jongbloed; Harry A M Twaalfhoven; Robert Veerhuis; Marinus A Blankenstein; Charlotte E Teunissen
Journal:  Front Neurol       Date:  2015-09-29       Impact factor: 4.003

5.  Immune and Epstein-Barr virus gene expression in cerebrospinal fluid and peripheral blood mononuclear cells from patients with relapsing-remitting multiple sclerosis.

Authors:  Caterina Veroni; Fabiana Marnetto; Letizia Granieri; Antonio Bertolotto; Clara Ballerini; Anna Maria Repice; Lucia Schirru; Giancarlo Coghe; Eleonora Cocco; Eleni Anastasiadou; Maria Puopolo; Francesca Aloisi
Journal:  J Neuroinflammation       Date:  2015-07-14       Impact factor: 8.322

Review 6.  Cerebrospinal fluid biomarkers of neurovascular dysfunction in mild dementia and Alzheimer's disease.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  J Cereb Blood Flow Metab       Date:  2015-04-22       Impact factor: 6.200

7.  Sphingomyelin as a myelin biomarker in CSF of acquired demyelinating neuropathies.

Authors:  Giovanna Capodivento; Davide Visigalli; Martina Garnero; Roberto Fancellu; Michela Demetra Ferrara; Abdul Basit; Zeeshan Hamid; Vito Paolo Pastore; Silvano Garibaldi; Andrea Armirotti; Gianluigi Mancardi; Carlo Serrati; Elisabetta Capello; Angelo Schenone; Lucilla Nobbio
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

8.  Metabolomic signatures associated with disease severity in multiple sclerosis.

Authors:  Pablo Villoslada; Cristina Alonso; Ion Agirrezabal; Ekaterina Kotelnikova; Irati Zubizarreta; Irene Pulido-Valdeolivas; Albert Saiz; Manuel Comabella; Xavier Montalban; Luisa Villar; Jose Carlos Alvarez-Cermeño; Oscar Fernández; Roberto Alvarez-Lafuente; Rafael Arroyo; Azucena Castro
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-01-27

9.  Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study.

Authors:  C E Leurs; Ham Twaalfhoven; B I Lissenberg-Witte; V van Pesch; I Dujmovic; J Drulovic; M Castellazzi; T Bellini; M Pugliatti; J Kuhle; L M Villar; J C Alvarez-Cermeño; R Alvarez-Lafuente; H Hegen; F Deisenhammer; L M Walchhofer; E Thouvenot; M Comabella; X Montalban; L Vécsei; C Rajda; D Galimberti; E Scarpini; A Altintas; K Rejdak; J L Frederiksen; G Pihl-Jensen; Peh Jensen; M Khalil; M M Voortman; F Fazekas; A Saiz; D La Puma; M Vercammen; L Vanopdenbosch; Bmj Uitdehaag; J Killestein; C Bridel; C Teunissen
Journal:  Mult Scler       Date:  2019-05-08       Impact factor: 6.312

10.  Accelerating drug development for Alzheimer's disease through the use of data standards.

Authors:  Jon Neville; Steve Kopko; Klaus Romero; Brian Corrigan; Bob Stafford; Elizabeth LeRoy; Steve Broadbent; Martin Cisneroz; Ethan Wilson; Eric Reiman; Hugo Vanderstichele; Stephen P Arnerić; Diane Stephenson
Journal:  Alzheimers Dement (N Y)       Date:  2017-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.